TEVA•benzinga•
JP Morgan Upgrades Teva Pharmaceutical Indus to Overweight, Raises Price Target to $23
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 12, 2025 by benzinga